The present invention provides a novel crystalline form of [R-(R*,R*)]-2-(4-fluorophenyl)-[beta],[delta]-dihydroxy-5-(1-mthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptanoic acid hemi-calcium salt (atorvastatin hemi-calcium salt) of the following formula 1, which is known to be useful as a drug, a hydrate thereof and a preparation method thereof:

The invention provides a process for the production of a compound of formula (I), said process comprising reacting a compound of formula (II) with a compound of formula (III) wherein R1 and R2 may be the same or different and are selected from H

The invention provides a process for the production of 1 a compound of formula (I), said process comprising reacting a compound of formula (II), with a compound of formula (III), wherein R1 and R2 may be the same or different and are selected from H

The present invention provides a novel crystalline form of [R-(R*R*)]-2-(4-fluorophenyl)--dihydroxy-5-(1-mthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptanoic acid hemi-calcium salt (atorvastatin hemi-calcium salt) of the following formula 1 which is known to be useful as a drug a hydrate thereof and a preparation method thereof:

Compositions and methods are provided for preventing or treating the pre-clinical early-stages of inflammatory diseases, including autoimmune diseases, degenerative inflammatory diseases, metabolic inflammatory diseases, chronic infection associated with inflammation, cancer associated with inflammation, and other inflammatory diseases by administration to an individual of an effective dose of a synergistic combination of active agents comprising or consisting essentially of an aminoquinoline, e...

Disclosed are a bilayered composite tablet formation comprising (a) a first layer comprising irbesartan or a pharmaceutically acceptable salt thereof

Compositions and methods are provided for preventing or treating the pre-clinical early-stages of inflammatory diseases, including autoimmune diseases, degenerative inflammatory diseases, metabolic inflammatory diseases, chronic infection associated with inflammation, cancer associated with inflammation, and other inflammatory diseases by administration to an individual of an effective dose of a synergistic combination of active agents comprising or consisting essentially of an aminoquinoline, e...

The present invention relates to oxidative degradation products of atorvastatin calcium and the process of the preparation thereof. The present invention also relates to atorvastatin calcium substantially free of oxidative degradation products and the pharmaceutical compositions containing such atorvastatin calcium.

The present invention relates to the medical field, and discloses a compound preparation of lercanidipine hydrochloride and atorvastatin calcium, which has a drug content per unit dosage of 5-20 mg of lercanidipine hydrochloride and 0-80 mg of atorvastatin calcium. The present invention also particularly provides a compound preparation in the form of tablets, which comprises lercanidipine hydrochloride and atorvastatin calcium as main drugs, and calcium carbonate, microcrystalline cellulose, sod...